Refine your search
Collections
Journals
Year
A B C D E F G H I J K L M N O P Q R S T U V W X Y Z All
Mrudula, Giri
- Treatment of Myocardial Infarction by Stem Cell Based Therapy
Abstract Views :234 |
PDF Views:65
Authors
Affiliations
1 Krupanidhi College of Pharmacy, Chikkabellandur, Carmelaram, Bangalore - 560 035, Karnataka, IN
1 Krupanidhi College of Pharmacy, Chikkabellandur, Carmelaram, Bangalore - 560 035, Karnataka, IN
Source
Journal of Pharmaceutical Research, Vol 16, No 1 (2017), Pagination: 4-13Abstract
Purpose: Recently myocardial infarction is one of the leading causes of death worldwide. Myocardial infarction leads to the serious consequences which cause increase in mortality and morbidity. In myocardial infarction there is permanent loss of cardiomyocytes which results an irreversible loss of cardiac function. Cardiac repair requires the replacement, restoration and regeneration of heart function. Conventional therapies such as revascularization, percutaneous coronary intervention (PCI) and coronary artery bypass grafting (CABG) prevent the additional damage to heart muscle and also reduce the risk of future heart attack. However, there is need to develop a new therapy to improve the infracted area after the myocardial infarction and also to lower the mortality rate.
Approaches: The data were collected from various sources like journal articles, internet, textbooks, related materials in library and databases such as Pubmed, Science Direct, Springer, Google Scholar and so on.
Findings: Stem cell-based therapy is found to be a much more promising therapy when compared to other available therapies. Stem cells therapy shows significantly improved heart function after myocardial infarction, therefore decline into heart failure.
Conclusion: Recently the interest is stem cell based therapies which provide the potential benefit and have ability to improve the cardiac function. In this review, we highlight the benefits of stem cells in cardiac repair.
Keywords
Stem Cells, Totipotent, Pluripotent, Multipotent, Myocardial Infarction.Full Text
References
- Veronique L. R. Epidemiology of myocardial infarction. Medical Clinical of North America. 2007; 91(4):537 - 539.
- The PREMISE program,2015. Prevention of Recurrence of Myocardial Infarction and Stroke Study. World Health Organization. Country project.
- Upaganlawar A. Isoproterenol induced myocardial infarction. Protective Role of Natural Product. Journal of Pharmacology and Toxicology. 2011; 6(1):1-17.
- Ashton Faulkner. Stem Cell Therapy: A New Approach for Treatment of Myocardial Infarction. Stem Cell Research and Therapy. 2001; S1-004:4172-7633.
- Sheing-Tsung Kuo. Stem Cell Therapy for Acute Myocardial Infarction and Heart Failure- Past, Present and Future. Taiwan Society of Internal Medicine. 2009; 20:1-18.
- Gupta BD. An introduction to stem cells and debate surrounding them. Journal Indian Academy of Forensic Medicine. 2009; 31(3):267.
- ISSCR. International Society for Stem Cell Research. 2016.
- Anand Krishna K. Myocardial Infarction and stem cells. Journal of Pharmacy and BioAllied Science. 2011; 3(2):182-188.
- Acosta SA. Human Umbilical Cord Blood for Transplantation Therapy in Myocardial Infarction. Journal of Stem cell Research and Therapy. 2013 ; 4: 005.
- Risheen R. Stem Cell Therapy in Acute Myocardial Infarction. Journal of Clinical and Experimental Cardiology. 2012; S11-004:2155-9880.
- Frat C. Resident cardiac stem cells. Current Pharmaceutical Design. 2011; 17(30):3252-3257.
- Bradfute SB. Cardiac progenitor cells from adult myocardium: homing differentiation and fusion after infraction. Proceedings of the National Academy of Sciences of the United States. 2003; 100:12313-12318.
- Buckingham M.. Skeletal muscle stem cells. Current opinion in genetic and development. 2008; 18(4):330336.
- Shah V.K. Stem Cell Therapy in Acute Myocardial Infarction: A plot of Gold or Pandora's Box. Stem Cell International. 2011; 20:20-24.
- Wam M. In vivo self renewal of c-kit+ Sca-1+ Lin (low/-) hemopoietic stem cells. Journal of Immunology. 1996; 156(9):3207-3214.
- Spangrude GJ. Purification and characteri-zation of mouse hematopoietic stem cells. Science. 1999; 241(4861):58-62.
- Pittenger MF. Multilineage potential of adult human mesenchymal stem cel ls. Science. 1999; 284(5411):143-147.
- M. ichew M. “Expression of VEGFR-2 and AC133 by circulating human CD34 (+) Cells identifies a population of function endothelial precursors”. Blood. 2000; 95(3):952-958.
- Calvin CS. Current Stem Cell Delivery Method for Myocardial Repair. Biomedical Research International. 2013 ; 4:15.
- Howard T. Walpole. Option for Stem Cell Delivery in Cardiology. Cardiac Catheteri-zation Laboratory. 2014; 2(1):e707.
- Mummery CL. Challenges in using stem cell for cardiac repair. Science Translation Medicine. 2010;2:17.
- Halkos ME. Intravenous infusion of mesenchymal stem cell enhances regional perfusion and improves ventricular function in a porcine model of myocardial infarction. Basic Research in Cardiology. 2008; 103(6):525-536.
- Dib N. Recommendations for successful training on method of delivery of biologist for cardiac regeneration: a report of the International Society for Cardiovascular Translation Research. Journal of the American College of Cardiology. 2010; 3(3):265-275.
- Pilio G. Direct minimally invasive intramyo-cardial injection of bone marrow derived AC133+ stem cell in patient with refractory ischemia: preliminary result. Thoracic and Cardiovascular Surgeon. 2008; 56(2):7176.
- Grossman PM. Incomplete retention after direct myocardial injec t ion. Catheter i zat ion and Cardiovascular Intervention. 2002; 55(3):392-397.
- Mozid AM. Stem cell therapy for heart diseases. British Medical Bulletin. 2011; 98(1):143-159.
- Sherman W. Catheter based delivery of cells to the heart. Natural Clinical Practice Cardiovascular Medicine. 2006; 3(1):S57-S64.
- Thompson CA. Percutaneous transvenous cellular cardiomyoplasty: a novel nonsurgical approach for myocardial cell transplantation. Journal of the American College of Cardiology. 2003; 41(11):1964-1971.
- Siminiak T. Post infarction heart failure: surgical and trans-coronary-venous transplan-tation of autologous myoblast. Natural Clinical Practice Cardiovascular Medicine. 2006; 3(1):S46-S51.
- Saccheetti A. Transendocardial delivery of autologous bone marrow enhances collateral perfusion and regional function in pig and chronic experimental myocardial ischemia. Journal of the American College of Cardiology. 2001; 37(6):1726-1732.
- Perin EC. Assessing myocardial viability and infract transmurality with left ventricular electromechanical mapping in patient with stable coronary artery disease: validation by delayed- enhancement magnetic resonance imaging. Circulation. 2002; 106(8):957-961.
- Widimsky P. Intracoronary Transplantation of bone marrow stem cells: background, technique and limitation. European Heart Journal Supplement. 2006; 8:H16-H22.
- Copland IB. Mesenchymal stromal cells for cardiovascular disease. Journal of Cardio-vascular Disease Research. 2011; 2(1); 3-13.
- Suzuki K. Development of a novel method for cell transplantation through the coronary artery. Circulation. 2000; 102(19):III359-III364.
- Yokoyama SI. A strategy of retrograde injection of bone marrow mononuclear cells into the myocardial for the treatment of ischemic heart disease. Journal of Molecular and Cellular Cardiology. 2006; 40(1):24-34.
- Vicario J. One year follow-up of transcoronary sinus administration of autologous bone marrow in patient with chronic ref ractory angina. Cardiovascular Revascularization Medicine. 2005; 6(3):99-107.
- Sui R. The current status of engineering myocardial tissue. Stem Cell Review and Report. 2011; 7(1):172180.
- Li Z. High- efficiency matrix modulus- induced cardiac differentiation of human mesenchymal stem cell inside a thermo sensitive hydrogel. Acta Biomaterialia. 2012; 8(10): 3586-3595.
- Miyahara Y. Monolayered mesenchymal stem cell repair scarred myocardium after myocardial infarction. Nature Medicine. 2006; 12(4):459-465.
- Hou D. Radio labeled cell distribution after intramyocardial, intracoronary and interstitial retrograde coronary venous delivery: implication for current clinical trials. Circulation. 2005; 112(9):I150-I156.
- Andrew J. Stem Cell Therapy for Cardiac Repair. Circulation. 2006; 114:339-352.
- Orlic D. Bone marrow cells regenerate infracted myocardium. Nature. 2001; 401:701-705.
- Olivares EL. Bone marrow stromal cells improve cardiac performance in healed infracted rat hearts. American Journal of Physiology. 2004; 287:H464-470.
- Schuster MD. Myocardial neovascularization by bone marrow angioblast results in cardiomyocyte regeneration. American Journal of Physiology. 2004; 287:H525-H532.
- Tuch BE. Stem cells- a clinical update. Australian Family Physician. 2006; 35(6):719-721.
- Mitsui K. The homeoprotein Nanog is required for maintenance of pluripotency in mouse epiblast and ES cells. Cell. 2003; 113(5):631-642.
- He JQ. Human embryonic stem cells develop into multiple types of cardiac myocytes: action potential characterization. Circulation Research. 2003; 93(1):3239.
- Vanderlaan RD. Electrophysiological profiling of cardiomyocytes in embryonic bodies derived from embryonic stem cells. Circulation Research. 2003; 93(1):1-3.
- Vawda R. Stem cells therapies for perinatal brain injuries. Seminars in Fetal and Neonatal Medicine.2001; 12(4):259-272.
- Liu S. Mammary stem cells, self renewal pathways and carcinogenesis. Breast Cancer Research. 2005; 7(3):86-95.
- Rolletschek A. Embryonic stem cell-derived cardiac, neuronal and pancreatic cells as model systems to study toxicological effects. Toxicology Letter. 2004; 149(1-3): 369-391.
- Korbling M. Adult stem cells tissue repair- a new therapeutic concept. New England Journal of Medicine. 2003; 349(6):570-582.
- Alonso L. Stem cells in the skin: waste not, Wnt not. Genes development. 2003; 17(10):1189-1200.
- Pharmacoeconomic Evaluation in End Stage Renal Diseased Patients
Abstract Views :235 |
PDF Views:67
Authors
Affiliations
1 Department of Pharmacology, Sultan-ul-Uloom College of Pharmacy, Mount Peasant, 8-2-249, Road No. 3, Banjara Hills, Hyderabad-34, Telangana State, IN
2 Department of Pharmacology, Krupanidhi College of Pharmacy, Chikkabellandur, Carmelaram Post, Bangalore-35, Karnataka, IN
1 Department of Pharmacology, Sultan-ul-Uloom College of Pharmacy, Mount Peasant, 8-2-249, Road No. 3, Banjara Hills, Hyderabad-34, Telangana State, IN
2 Department of Pharmacology, Krupanidhi College of Pharmacy, Chikkabellandur, Carmelaram Post, Bangalore-35, Karnataka, IN
Source
Journal of Pharmaceutical Research, Vol 16, No 1 (2017), Pagination: 14-18Abstract
Aim : The purpose of this project is to evaluate the economic evaluation of End Stage Renal Diseased patients within the context of continued economic uncertainty and pressure on healthcare resource use. Objective : These findings are important to find out the impact of cost of haemodialysis on patients suffering from ESRD. Further studies related to costs and outcome, otherwise known as pharmacoeconomic studies, are needed to analyse the cost evaluation in End Stage Renal Dialysis patients.
Methodology : A prospective observational study was conducted for a period of Eight months (December 2015 to July 2016) at a tertiary care hospital in the Inpatient Nephrology Department. Patients coming on outpatient basis were selected for the study. Patients were allotted in different shifts either in morning, afternoon or evening, based on their preferences. The patients were followed up for a period of 8 months. The patient sociodemographics, cost details of dialysis, hospital costs, comorbities diseases and their cost, adverse reactions occurred during dialysis, cost to manage such adverse reactions, regularity, affordability, outcome and patient satisfaction to dialysis, etc. were collected prospectively.
Result : The total cost per session was found to be around INR 4500. Fifty six percent contributes direct medical cost whereas 20% contributes direct non medical cost. Twenty four percent cost was due to indirect costs. Since the patients are paying from their own pocket, only the upper or upper middle class patient can undergo haemodialysis regularly.
Keywords
Cost Analysis, End Stage Renal Disease, Haemodialysis, Pharmacoeconomics.Full Text
References
- Mani MK. Prevention of chronic renal failure at the community level. Kidney Int. 2003; 83: S86–S89.
- Agarwal SK, Dash SC, Irshad M, Raju S, Singh R, Pandey RM. Prevalence of chronic renal failure in adults in Delhi, India. Nephrol Dial Transplant. 2005; 20:1638–42.
- Agarwal SK, Dash SC. Spectrum of renal diseases in India in adults. J Assoc Physicians India.2000; 48: 594–600.
- Modi GK and Jah V. The incidence of end-stage renal disease in India: A population-based study. Kidney International. 2006; 70 (12): 2131–2133.
- Mani MK. Chronic renal failure in India. Nephrol Dial Transplant. 1993; 8: 684–689.
- Mittal S, Kher V, Gulati S . Chronic renal failure in India. Ren Fail. 1997; 19: 753–770
- Sakhuja V, Jha V, Ghosh AK. Chronic renal failure in India. Nephrol Dial Transplant. 1994; 9: 871–872
- Suja R, Anju V, Anju J, Neethu P, Peeyush, Saraswathy R. Economic evaluation of end stage renal disease patients undergoing hemodialysis. J Pharm Bioallied Sci. 2012; 4(2): 107–111.
- Surendra G. Pharmacoeconomics: A review. Asian Journal of Pharmaceutical and Clinical Research. 2009; 2(3): 15-26.
- Devi P, Rao M, Sigamani A. Prevalence, risk factors and awareness of hypertension in India: a systematic review. J Hum Hypertens. 2013; 27: 281–287.
- Al-Ramahi R. Medication prescribing patterns among chronic kidney disease patients in a hospital in Malaysia. Saudi J Kidney Dis Transp. 2012; 23: 403-408.
- Bajait CS, Pimpalkhute SA, Sontakke SD, Jaiswal KM, Dawri AV. Prescribing pattern of medicines in chronic kidney disease with emphasis on phosphate binders. Indian J Pharmacol. 2014; 46: 35-39.
- Becker G, Wheeler D, Zeeuw D. Kdigo. Clinical practices guideline for the management of blood pressure in chronic kidney disease. Kidney Int. 2012; 2: S337-414.
- A Review on Drug Interactions in Oral Hypoglycemic Drugs by Mechanism of Cytochrome P450 Enzyme Inhibition
Abstract Views :250 |
PDF Views:90
Authors
Affiliations
1 Krupanidhi College of Pharmacy, #12/1, Chikkabellandur, Carmelaram Post, Varthur Hobli , Bangalore - 560035, KA, IN
1 Krupanidhi College of Pharmacy, #12/1, Chikkabellandur, Carmelaram Post, Varthur Hobli , Bangalore - 560035, KA, IN
Source
Journal of Pharmaceutical Research, Vol 16, No 2 (2017), Pagination: 154-159Abstract
Purpose: Drug interaction is a phenomenon that has to be thoroughly investigated in order to avoid adverse effects. This review article highlights the drug interaction of oral hypoglycemics by mechanism of cytochrome P450 enzyme inhibition.
Approach: Published articles from PubMed and other sources were used to review and compile these drug interaction studies.
Findings: Drug interaction in oral hypoglycemics by mechanism of cytochrome P450 enzyme inhibition can increase the risk of hypoglycemia in diabetic patients and hence dose adjustments may be required.
Conclusion: These drug interaction studies are essential for patients suffering from diabetes mellitus as it prevents the risk of occurrence of hypoglycemia. This information is also important for the prescribing physicians as dose alteration or alternate drugs need to administered in case of concomitant administration of drugs in case of polypharmacy.
Keywords
Drug Interaction, CYP450 Enzyme, Oral Hypoglycemics, Food-Drug Interaction.Full Text
References
- Mallet L, hypoglycemia A, Huang A. The challenge of managing drug interactions in elderly people. The Lancet. 2007 Jul 20;370(9582):185-91.
- lberti KG, Zimmet PF. Definition, diagnosis and classification of diabetes mellitus and its complications. Part 1: diagnosis and classification of diabetes mellitus. Provisional report of a WHO consultation. Diabetic medicine. 1998 Jul 1;15(7):539-53.
- Peart GF, Boutagy J, Shenfield GM. The metabolism of glyburide in subjects of known debrisoquin phenotype. Clinical Pharmacology & Therapeutics. 1989 Mar 1;45(3):277-84.
- Jönsson A, Karlsson MO, Melander A. Concentration‐effect relations of glibenclamide and its active metabolites in man: modelling of Pharmacokinetics and Pharmacodynamics. British journal of clinical pharmacology. 1997 Apr 1;43(4):373-81.
- Wensing G. Topics in clinical pharmacology: Glipizide: an oral hypoglycemic drug. The American journal of the medical sciences. 1989 Jul 1;298(1):69-71.
- Brian WR. Hypoglycemic agents, In: Levy RH, Thummel KE, Tranger WF, Haunsten PD, Eichelbaum M, eds. Metabolic drug interactions. Philadelphia: Lippincott Williams & Wilkins; 2000. 429-43.
- Kidd RS, Straughn AB, Meyer MC, Blaisdell J, Goldstein JA, Dalton JT. Pharmacokinetics of chlorpheniramine, phenytoin, glipizide and nifedipine in an individual homozygous for the CYP2C9* 3 allele. Pharmacogenetics and Genomics. 1999 Feb 1;9(1):71-80.
- Lamy PP. Classification of drug interactions. Drug Information Journal. 1972 Jan;6(1):99-107.
- Prescott LF. Drug interaction during absorption. Naunyn-Schmiedeberg's archives of pharmacology. 1977 Jan 1;297(1):S29-31.
- Shitara Y, Horie T, Sugiyama Y. Transporters as a determinant of drug clearance and tissue distribution. European journal of pharmaceutical sciences. 2006 Apr 30;27(5):425-46.
- Lu Z, Zhang R, Diasio RB. Population characteristics of hepatic dihydropyrimidine dehydrogenase activity, a key metabolic enzyme in 5‐fluorouracil chemotherapy. Clinical Pharmacology & Therapeutics. 1995 Nov 1;58(5):512-22.
- Marchitti SA, Brocker C, Stagos D, Vasiliou V. Non-P450 aldehyde oxidizing enzymes: the aldehyde dehydrogenase superfamily. Expert opinion on drug metabolism & toxicology. 2008 Jun 1;4(6):697-720.
- Wormhoudt LW, Commandeur JN, Vermeulen NP. Genetic polymorphisms of human N-acetyltransferase, cytochrome P450, glutathione-S-transferase, and epoxide hydrolase enzymes: relevance to xenobiotic metabolism and toxicity. Critical reviews in toxicology. 1999 Jan 1;29(1):59-124.
- Willey JC, Coy E, Brolly C, Utell MJ, Frampton MW, Hammersley J, Thilly WG, Olson D, Cairns K. Xenobiotic metabolism enzyme gene expression in human bronchial epithelial and alveolar macrophage cells. American journal of respiratory cell and molecular biology. 1996 Mar;14(3):262-71.
- Tom Lynch, Amy Price. The effect of cytochrome P450 metabolism on drug response, interactions, and adverse effects. Am Fam Physician. 2007;76:3916.
- Shitara Y, Sato H, Sugiyama Y. Evaluation of drug-drug interaction in the hepatobiliary and renal transport of drugs. Annu. Rev. Pharmacol. Toxicol.. 2005 Feb 10;45:689-723.
- Krentz AJ, Bailey CJ. Oral antidiabetic agents. Drugs. 2005 Feb 1;65(3):385-411.
- Groop LC. Sulfonylureas in NIDDM. Diabetes care. 1992 Jun 1;15(6):737-54.
- Dornhorst A. Insulinotropic meglitinide analogues. The Lancet. 2001 Nov 17;358(9294):1709-16.
- Goldstein BJ. Current views on the mechanism of action of thiazolidinedione insulin sensitizers. Diabetes technology & therapeutics. 1999 Sep 1;1(3):267-75.
- Lebovitz HE. Alpha-glucosidase inhibitors. Endocrinology and metabolism clinics of North America. 1997 Sep 1;26(3):539-51.
- Thornberry NA, Gallwitz B. Mechanism of action of inhibitors of dipeptidylpeptidase4 (DPP-4). Best Practice & Research Clinical Endocrinology & Metabolism. 2009 Aug 31;23(4):479-86.
- Neumiller JJ. Differential chemistry (structure), mechanism of action, and pharmacology of GLP-1 receptor agonists and DPP-4 inhibitors. Journal of the American Pharmacists Association: JAPhA. 2008 Dec;49:S16-29.
- Reda TK, Geliebter A, Pi‐Sunyer FX. Amylin, food intake, and obesity. Obesity research. 2002 Oct 1;10(10):1087-91.
- Neumiller JJ, White JR, Campbell RK. Sodium-glucose co-transport inhibitors. Drugs. 2010 Mar 1;70(4):377-85.
- Hansen JM, Christensen LK. Drug interactions with oral sulphonylurea hypoglycaemic drugs. Drugs. 1977 Jan 1;13(1):24-34.
- Kirchheiner J, Roots I, Goldammer M, Rosenkranz B, Brockmöller J. Effect of genetic polymorphisms in cytochrome P450 (CYP) 2C9 and CYP2C8 on the pharmacokinetics of oral antidiabetic drugs. Clinical pharmacokinetics. 2005 Dec 1;44(12):1209-25.
- Li XQ, Andersson TB, Ahlström M, Weidolf L. Comparison of inhibitory effects of the proton pump-inhibiting drugs omeprazole, esomeprazole, lansoprazole, pantoprazole, and rabeprazole on human cytochrome P450 activities. Drug metabolism and disposition. 2004 Aug 1;32(8):821-7.
- Rajendra SV, Narsu L, Ramachandra Setty S. Influence of rabeprazole on antidiabetic effect of sulfonylureas in diabetic rats. Pharmacologyonline. 2008;3:1017-23.
- Hatanaka T. Clinical pharmacokinetics of pravastatin. Clinical pharmacokinetics. 2000 Dec 1;39(6):397-412.
- Jacobsen W, Kirchner G, Hallensleben K, Mancinelli L, Deters M, Hackbarth I, Benet LZ, Sewing KF, Christians U. Comparison of cytochrome P-450dependent metabolism and drug interactions of the 3-hydroxy-3methylglutaryl-CoA reductase inhibitors lovastatin and pravastatin in the liver. Drug metabolism and disposition. 1999 Feb 1;27(2):173-9.
- Transon C, Leemann T, Dayer P. In vitro comparative inhibition profiles of major human drug metabolising cytochrome P450 isozymes (CYP2C9, CYP2D6 and CYP3A4) by HMG-CoA reductase inhibitors. European journal of clinical pharmacology. 1996 May 1;50(3):209-15.
- Satyanarayana S, Chandrasekhar MS, Palakshi Gouda O, Eswar Kumar K. Drug-drug interaction between Pravastatin and Gliclazide in animal models. Scholarly Research Exchange. 2008 Sep 3;2008.
- Sahi J, Black CB, Hamilton GA, Zheng X, Jolley S, Rose KA, Gilbert D, LeCluyse EL, Sinz MW. Comparative effects of thiazolidinediones on in vitro P450 enzyme induction and inhibition. Drug Metabolism and Disposition. 2003 Apr 1;31(4):439-46.
- Chaitanya Gadiko , Prakash Pamu, Eswar Kumar Kilari. Effect of amiodarone on the pharmacodynamics of gliclazide in animal models. International Journal of Pharmacy and Pharmaceutical Sciences. 2013;5(4):290-93.
- Mastan SK, Kumar KE. Influence of atazanavir on the pharmacodynamics and pharmacokinetics of gliclazide in animal models. International Journal of Diabetes Mellitus. 2010 Apr 30;2(1):56-60.
- Kumar GN, Rodrigues AD, Buko AM, Denissen JF. Cytochrome P450-mediated metabolism of the HIV-1 protease inhibitor ritonavir (ABT-538) in human liver microsomes. Journal of Pharmacology and Experimental Therapeutics. 1996 Apr 1;277(1):423-31.
- Mastan SK, Kumar KE. Influence of non-nucleoside reverse transcriptase inhibitors (efavirenz and nevirapine) on the pharmacodynamic activity of gliclazide in animal models. Diabetology & metabolic syndrome. 2009 Oct 9;1(1):15.
- Mouly S, Lown KS, Kornhauser D, Joseph JL, Fiske WD, Benedek IH, Watkins PB. Hepatic but not intestinal CYP3A4 displays dose‐dependent induction by efavirenz in humans. Clinical Pharmacology & Therapeutics. 2002 Jul 1;72(1):1-9.
- Mastan S, Eswar Kumar K. Effect of ritonavir on the pharmacodynamics of gliclazide in animal models. Diabetologia Croatica. 2009;38(4):105-3.
- Brian WR, Srivastava PK, Umbenhauer DR, Lloyd RS, Guengerich FP. Expression of a human liver cytochrome P-450 protein with tolbutamide hydroxylase activity in Saccharomyces cerevisiae. Biochemistry. 1989 Jun;28(12):4993-9.
- Back DJ, Tjia JF, Karbwang J, Colbert J. In vitro inhibition studies of tolbutamide hydroxylase activity of human liver microsomes by azoles, sulphonamides and quinolines. British journal of clinical pharmacology. 1988 Jul 1;26(1):23-9.
- Sugita OS, Sawada YA, Sugiyama Y, Iga TA, Hanano MA. Kinetic analysis of tolbutamide-sulfonamide interaction in rabbits based on clearance concept. Prediction of species difference from in vitro plasma protein binding and metabolism. Drug metabolism and disposition. 1984 Jan 1;12(1):131-8.
- Sugita O, Sawada Y, Sugiyama Y, Iga T, Hanano M. Effect of sulfaphenazole on tolbutamide distribution in rabbits: Analysis of interspecies differences in tissue distribution of tolbutamide. Journal of pharmaceutical sciences. 1984 May 1;73(5):631-4.
- Komatsu K, Ito K, Nakajima Y, Kanamitsu SI, Imaoka S, Funae Y, Green CE, Tyson CA, Shimada N, Sugiyama Y. Prediction of in vivo drug-drug interactions between tolbutamide and various sulfonamides in humans based on in vitro experiments. Drug Metabolism and Disposition. 2000 Apr 1;28(4):475-81.
- Hidaka M, Fujita KI, Ogikubo T, Yamasaki K, Iwakiri T, Okumura M, Kodama H, Arimori K. Potent inhibition by star fruit of human cytochrome P450 3A (CYP3A) activity. Drug metabolism and disposition. 2004 Jun 1;32(6):581-3.
- Hidaka M, Okumura M, Fujita KI, Ogikubo T, Yamasaki K, Iwakiri T, Setoguchi N, Arimori K. Effects of pomegranate juice on human cytochrome p450 3A (CYP3A) and carbamazepine pharmacokinetics in rats. Drug metabolism and disposition. 2005 May 1;33(5):644-8.
- Fujita KI, Hidaka M, Takamura N, Yamasaki K, Iwakiri T, Okumura M, Kodama H, Yamaguchi M, Ikenoue T, Arimori K. Inhibitory effects of citrus fruits on cytochrome P450 3A (CYP3A) activity in humans. Biological and Pharmaceutical Bulletin. 2003;26(9):1371-3.
- Hidaka M, Nagata M, Kawano Y, Sekiya H, Kai H, Yamasaki K, Okumura M, Arimori K. Inhibitory effects of fruit juices on cytochrome P450 2C9 activity in vitro. Bioscience, biotechnology, and biochemistry. 2008 Feb 23;72(2):40611.
- Nagata M, Hidaka M, Sekiya H, Kawano Y, Yamasaki K, Okumura M, Arimori K. Effects of pomegranate juice on human cytochrome P450 2C9 and tolbutamide pharmacokinetics in rats. Drug metabolism and disposition. 2007 Feb 1;35(2):302-5.
- Bailey DG, Dresser GK. Interactions between grapefruit juice and cardiovascular drugs. American Journal of Cardiovascular Drugs. 2004 Sep 1;4(5):281-97.